Aptorum Group (Aptorum Group) Days Payable : 0.00 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Days Payable?

Aptorum Group's average Accounts Payable for the six months ended in Jun. 2023 was $0.00 Mil. Aptorum Group's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.43 Mil. Hence, Aptorum Group's Days Payable for the six months ended in Jun. 2023 was 0.00.

The historical rank and industry rank for Aptorum Group's Days Payable or its related term are showing as below:

APM's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 147.95
* Ranked among companies with meaningful Days Payable only.

Aptorum Group's Days Payable stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

Aptorum Group Days Payable Historical Data

The historical data trend for Aptorum Group's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Days Payable Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Aptorum Group's Days Payable

For the Biotechnology subindustry, Aptorum Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptorum Group's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Days Payable distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Days Payable falls into.

Aptorum Group Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aptorum Group's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1.216	*	365
=	0					/	1.216	*	365
=	0.00

Aptorum Group's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.426	*	365 / 2
=	0					/	0.426	*	365 / 2
=	0.00

Aptorum Group Days Payable Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.